                         SEQUENCE LISTING

<110>  Primmune Therapeutics, Inc.
 
<120>  SARS-3CL Protease Inhibitors

<130>  055014-503001WO

<140>  Herewith
<141>  Herewith

<150>  US 63/169,613
<151>  2021-04-01

<160>  1     

<170>  PatentIn version 3.5

<210>  1
<211>  14
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  The N-terminal lysine (K) forms an amide with 
       4-(dimethylaminoazo)benzene-4-carboxylic acid (Dabcyl)

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  The C-terminal of Glutamic acid (E) forms an amide with 
       (5-((2-Aminoethyl)amino)naphthalene-1-sulfonic acid) (Edans)

<400>  1

Lys Thr Ser Ala Val Leu Gln Ser Gly Phe Arg Lys Met Glu 
1               5                   10                  


